140 related articles for article (PubMed ID: 12725353)
21. Costs and savings associated with infection control measures that reduced transmission of vancomycin-resistant enterococci in an endemic setting.
Montecalvo MA; Jarvis WR; Uman J; Shay DK; Petrullo C; Horowitz HW; Wormser GP
Infect Control Hosp Epidemiol; 2001 Jul; 22(7):437-42. PubMed ID: 11583213
[TBL] [Abstract][Full Text] [Related]
22. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center.
Warren DK; Shukla SJ; Olsen MA; Kollef MH; Hollenbeak CS; Cox MJ; Cohen MM; Fraser VJ
Crit Care Med; 2003 May; 31(5):1312-7. PubMed ID: 12771596
[TBL] [Abstract][Full Text] [Related]
23. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality.
Pittet D; Tarara D; Wenzel RP
JAMA; 1994 May; 271(20):1598-601. PubMed ID: 8182812
[TBL] [Abstract][Full Text] [Related]
24. Outcomes and costs associated with a history of vancomycin exposure in patients with MRSA-related complicated bacteremia and infective endocarditis.
Brown J; Brown KA; Forrest A
Clin Ther; 2011 Oct; 33(10):1475-82. PubMed ID: 21925733
[TBL] [Abstract][Full Text] [Related]
25. Enterococcal bacteremia in a teaching hospital in the Central region of Saudi Arabia.
Al-Otaibi FE; Kambal AM; Baabbad RA
Saudi Med J; 2004 Jan; 25(1):21-5. PubMed ID: 14758373
[TBL] [Abstract][Full Text] [Related]
26. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections.
Kopp BJ; Nix DE; Armstrong EP
Ann Pharmacother; 2004 Sep; 38(9):1377-82. PubMed ID: 15266044
[TBL] [Abstract][Full Text] [Related]
27. Cost of intensive care unit-acquired bloodstream infections.
Laupland KB; Lee H; Gregson DB; Manns BJ
J Hosp Infect; 2006 Jun; 63(2):124-32. PubMed ID: 16621137
[TBL] [Abstract][Full Text] [Related]
28. Outcomes associated with vancomycin-resistant enterococci: a meta-analysis.
Salgado CD; Farr BM
Infect Control Hosp Epidemiol; 2003 Sep; 24(9):690-8. PubMed ID: 14510253
[TBL] [Abstract][Full Text] [Related]
29. The attributable cost and length of hospital stay because of nosocomial pneumonia in intensive care units in 3 hospitals in Argentina: a prospective, matched analysis.
Rosenthal VD; Guzman S; Migone O; Safdar N
Am J Infect Control; 2005 Apr; 33(3):157-61. PubMed ID: 15798670
[TBL] [Abstract][Full Text] [Related]
30. Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections.
Blot SI; Depuydt P; Annemans L; Benoit D; Hoste E; De Waele JJ; Decruyenaere J; Vogelaers D; Colardyn F; Vandewoude KH
Clin Infect Dis; 2005 Dec; 41(11):1591-8. PubMed ID: 16267731
[TBL] [Abstract][Full Text] [Related]
31. Financial consequences of hospital-acquired bacteraemia in three Belgian hospitals in 2003 and 2004.
Pirson M; Leclercq P; Jackson T; Leclercq M; Garrino M; Sion C
J Hosp Infect; 2008 Jan; 68(1):9-16. PubMed ID: 18055065
[TBL] [Abstract][Full Text] [Related]
32. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality.
Classen DC; Pestotnik SL; Evans RS; Lloyd JF; Burke JP
JAMA; 1997 Jan 22-29; 277(4):301-6. PubMed ID: 9002492
[TBL] [Abstract][Full Text] [Related]
33. Systemic inflammatory response syndrome in nosocomial bloodstream infections with Pseudomonas aeruginosa and Enterococcus Species: comparison of elderly and nonelderly patients.
Marra AR; Bar K; Bearman GM; Wenzel RP; Edmond MB
J Am Geriatr Soc; 2006 May; 54(5):804-8. PubMed ID: 16696747
[TBL] [Abstract][Full Text] [Related]
34. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs?
Abramson MA; Sexton DJ
Infect Control Hosp Epidemiol; 1999 Jun; 20(6):408-11. PubMed ID: 10395142
[TBL] [Abstract][Full Text] [Related]
35. Hospital-acquired, laboratory-confirmed bloodstream infection: increased hospital stay and direct costs.
Orsi GB; Di Stefano L; Noah N
Infect Control Hosp Epidemiol; 2002 Apr; 23(4):190-7. PubMed ID: 12002233
[TBL] [Abstract][Full Text] [Related]
36. Economic analysis of vancomycin-resistant enterococci at a Canadian hospital: assessing attributable cost and length of stay.
Lloyd-Smith P; Younger J; Lloyd-Smith E; Green H; Leung V; Romney MG
J Hosp Infect; 2013 Sep; 85(1):54-9. PubMed ID: 23920443
[TBL] [Abstract][Full Text] [Related]
37. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs.
Kirkland KB; Briggs JP; Trivette SL; Wilkinson WE; Sexton DJ
Infect Control Hosp Epidemiol; 1999 Nov; 20(11):725-30. PubMed ID: 10580621
[TBL] [Abstract][Full Text] [Related]
38. Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus bloodstream infection?
Ben-David D; Novikov I; Mermel LA
Infect Control Hosp Epidemiol; 2009 May; 30(5):453-60. PubMed ID: 19344266
[TBL] [Abstract][Full Text] [Related]
39. [Study of costs associated with catheter-related bacteremia].
Morís de la Tassa J; Fernández Muñoz P; Antuña Egocheaga A; Gutiérrez del Río MC; de la Fuente García B; Cartón Sánchez JA
Rev Clin Esp; 1998 Oct; 198(10):641-6. PubMed ID: 9844450
[TBL] [Abstract][Full Text] [Related]
40. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit.
Digiovine B; Chenoweth C; Watts C; Higgins M
Am J Respir Crit Care Med; 1999 Sep; 160(3):976-81. PubMed ID: 10471627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
